XNCR Latest Press Releases

-- October 26, 2026 --

Defining Moments in the Race for Biotech Breakthroughs Globe Newswire 10:44 AM

-- October 25, 2026 --

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors Business Wire 4:35 AM

-- October 19, 2026 --

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Business Wire 7:01 AM

-- August 5, 2026 --

Xencor Reports Second Quarter 2026 Financial Results Business Wire 4:01 PM

-- July 29, 2026 --

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter Business Wire 4:01 PM

-- July 17, 2026 --

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Business Wire 9:11 AM

-- July 6, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 11:20 AM

Market Data Delayed 15 Minutes